Securities Suits Allege VistaGen Therapeutics Misled Investors on Fasedienol PALISADE Trial

Legal Scrutiny Centers on Vistagen’s Fasedienol Trial Claims

Multiple U.S. law firms are pressing securities claims against VistaGen Therapeutics, focusing on the company’s public statements about fasedienol and its PALISADE clinical program. The suits allege VistaGen creates a misleading picture of its Phase 3 prospects by citing positive PALISADE‑2 signals and operational changes to PALISADE‑3 as evidence that the later study is confirmatory. The complaints, filed or publicized in the past 72 hours, say those representations give a false sense of reduced clinical risk for the investigational pherine candidate aimed at acute treatment of social anxiety disorder (SAD).

The filings and notices assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5, alleging that VistaGen overstated PALISADE‑2 results, masked endpoint uncertainties and downplayed the possibility of Phase 3 failure. Plaintiffs argue the company’s characterizations of PALISADE‑2 and the purported enhancements to PALISADE‑3 infected the market during a defined class period from April 1, 2024 through Dec. 16, 2025, and that investors suffered losses when the underlying truth emerged. The litigation frames the dispute as centered on clinical disclosure and risk communication rather than on changes in underlying science or regulatory policy.

The litigation remains at the pre‑certification stage and could affect how biotechnology companies describe early‑stage trial outcomes and planned pivotal studies. Law firms involved stress that class members need not be appointed lead plaintiff to participate in any recovery, but moving for lead status can give a plaintiff greater influence over litigation strategy. Firms are urging affected shareholders to act ahead of a March 16, 2026 deadline to seek lead‑plaintiff appointment, and note contingency fee arrangements for victims seeking recovery.

Regulatory and clinical context

Fasedienol is an investigational pherine designed to act rapidly for episodic social anxiety, and confirmatory Phase 3 results are a common gateway to regulatory filings and commercialization in central nervous system indications. The disputes hinge on how VistaGen communicated trial endpoints, prior results and operational adjustments — areas that regulators and investors treat as material to assessing development risk.

Law firms and investor outreach

Rosen Law Firm, DJS Law Group and The Schall Law Firm are among the firms soliciting potential class members, each emphasizing securities litigation experience and investor recovery objectives. The firms publicly detail contact channels and encourage prompt inquiries while noting that the class has not yet been certified and that prospective plaintiffs should preserve their rights.